CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 258 enrolled
Drug / intervention
HMS5552 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02561338
NCT02561338Phase 2Completed
CompareCT.gov

A Multi-center, Randomized, Double-blind, Placebo-controlled, 12-week Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Population PK of HMS5552 in Type 2 Diabetic Adult Subjects

Hua Medicine Limited·interventional·Posted Sep 28, 2015·Updated Mar 10, 2020

In Brief

A Phase 2 clinical trial evaluating HMS5552 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 258 participants across 1 site.

Detailed Summary

This study evaluates the safety, tolerability, efficacy and population PK of HMS5552 in type 2 diabetic adult subjects,there will be 5 groups ,4 groups will receive HMS5552,while 1 will receive placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina
CollaboratorsTigermed Consulting Co., Ltd

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 28, 2015
Enrollment StartSep 1, 2015
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.8 years ago

Interventions

HMS5552drug

75mgQD

HMS5552drug

100mgQD

HMS5552drug

50mgBID

HMS5552drug

75mgBID

Placeboother

QD/BID